FI954964A - Användande av vWF-haltiga koncentrat som kombinationsterapi vid terapi med antitrombotika och fibrinolytika - Google Patents

Användande av vWF-haltiga koncentrat som kombinationsterapi vid terapi med antitrombotika och fibrinolytika Download PDF

Info

Publication number
FI954964A
FI954964A FI954964A FI954964A FI954964A FI 954964 A FI954964 A FI 954964A FI 954964 A FI954964 A FI 954964A FI 954964 A FI954964 A FI 954964A FI 954964 A FI954964 A FI 954964A
Authority
FI
Finland
Prior art keywords
therapy
vwf
antithrombotic
fibrinolytic
containing concentrates
Prior art date
Application number
FI954964A
Other languages
English (en)
Finnish (fi)
Other versions
FI954964A0 (sv
Inventor
Martin Reers
Gerhard Dickneite
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of FI954964A0 publication Critical patent/FI954964A0/sv
Publication of FI954964A publication Critical patent/FI954964A/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FI954964A 1994-10-20 1995-10-18 Användande av vWF-haltiga koncentrat som kombinationsterapi vid terapi med antitrombotika och fibrinolytika FI954964A (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4437544A DE4437544A1 (de) 1994-10-20 1994-10-20 Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika

Publications (2)

Publication Number Publication Date
FI954964A0 FI954964A0 (sv) 1995-10-18
FI954964A true FI954964A (sv) 1996-04-21

Family

ID=6531287

Family Applications (1)

Application Number Title Priority Date Filing Date
FI954964A FI954964A (sv) 1994-10-20 1995-10-18 Användande av vWF-haltiga koncentrat som kombinationsterapi vid terapi med antitrombotika och fibrinolytika

Country Status (20)

Country Link
US (1) US5571784A (sv)
EP (1) EP0713881A3 (sv)
JP (1) JPH08208504A (sv)
KR (1) KR960013383A (sv)
CN (1) CN1128168A (sv)
AU (1) AU708670B2 (sv)
CA (1) CA2160975A1 (sv)
CZ (1) CZ287878B6 (sv)
DE (1) DE4437544A1 (sv)
FI (1) FI954964A (sv)
HR (1) HRP950525A2 (sv)
HU (1) HU219595B (sv)
IL (1) IL115652A (sv)
NO (1) NO954175L (sv)
NZ (1) NZ280274A (sv)
PL (1) PL183182B1 (sv)
SK (1) SK129695A3 (sv)
TW (1) TW398977B (sv)
UY (1) UY24063A1 (sv)
ZA (1) ZA958838B (sv)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
AT405485B (de) * 1997-05-28 1999-08-25 Immuno Ag Eine das vwf-propeptid enthaltende pharmazeutische präparation
AT409335B (de) * 1998-11-10 2002-07-25 Immuno Ag Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
EP1148063A1 (de) * 2000-04-18 2001-10-24 Octapharma AG Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
JP2003284570A (ja) 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
DE102008032361A1 (de) * 2008-07-10 2010-01-21 Csl Behring Gmbh Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie
EP2536753B1 (en) * 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
ES2657291T3 (es) 2013-04-22 2018-03-02 Csl Ltd. Un complejo covalente de factor de von Willebrand y factor VIII asociado por un puente disulfuro
TWI580423B (zh) * 2013-12-24 2017-05-01 財團法人工業技術研究院 緩解或治療痛風之醫藥組合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
US5200510A (en) * 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US4774323A (en) * 1987-06-29 1988-09-27 Rorer Pharmaceutical Corporation Purification of von Willebrand Factor solutions using gel permeation chromatography
FR2619314B1 (fr) * 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US5204323B1 (en) 1988-10-06 1995-07-18 Ciba Geigy Corp Hirudin antidotal compositions and methods
GB8823480D0 (en) 1988-10-06 1988-11-16 Ciba Geigy Ag Antidote
FR2673632A1 (fr) * 1991-03-08 1992-09-11 Lille Transfusion Sanguine Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.
DE4115453A1 (de) 1991-05-11 1992-11-12 Knoll Ag Neue wirkstoffkombination
US5366869A (en) * 1991-11-08 1994-11-22 Sheldon Goldstein Multiple coagulation test device and method
DE4203965A1 (de) * 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
WO1994025582A1 (en) * 1993-04-23 1994-11-10 Bio-Technology General Corp. Method of enhancing thrombolysis

Also Published As

Publication number Publication date
CZ287878B6 (cs) 2001-03-14
CA2160975A1 (en) 1996-04-21
NZ280274A (en) 1997-01-29
IL115652A (en) 2000-08-31
UY24063A1 (es) 1995-10-24
PL183182B1 (pl) 2002-06-28
HU219595B (hu) 2001-05-28
AU3430495A (en) 1996-05-02
DE4437544A1 (de) 1996-04-25
US5571784A (en) 1996-11-05
PL311031A1 (en) 1996-04-29
ZA958838B (en) 1996-05-13
TW398977B (en) 2000-07-21
EP0713881A2 (de) 1996-05-29
NO954175D0 (no) 1995-10-19
CZ271995A3 (en) 1996-05-15
CN1128168A (zh) 1996-08-07
JPH08208504A (ja) 1996-08-13
EP0713881A3 (de) 1996-08-21
HUT73762A (en) 1996-09-30
HRP950525A2 (en) 1997-04-30
SK129695A3 (en) 1996-10-02
FI954964A0 (sv) 1995-10-18
NO954175L (no) 1996-04-22
HU9503031D0 (en) 1995-12-28
KR960013383A (ko) 1996-05-22
AU708670B2 (en) 1999-08-12
IL115652A0 (en) 1996-01-19

Similar Documents

Publication Publication Date Title
GB9701206D0 (en) Serine derivatives and their use as therapeutic agents
NO20000268L (no) Anvendelse av Lactobacillus for reduksjon av fibrinogen nivå i blod
AU3391395A (en) Morpholine derivatives and their use as therapeutic agents
ID17156A (id) Zat-zat anti koagulan yang berguna dalam pengobatan trombosis
GB9613003D0 (en) N-oxides of morpholine derivatives and their use as therapeutic agents
EE9800459A (et) Spiro-piperidiini derivaadid ja nende kasutamine terapeutiliste toimeainetena
GB9515775D0 (en) Piperidine derivatives and their use as therapeutic agents
DE69609353D1 (de) In der therapie verwendbare chinolin- und chinazolinverbindungen
CY2508B1 (en) Benzopyrans and their use as therapeutic agents
PL332136A1 (en) Benzamidine derivatives and their application an therapeutic agents being antagonists in respect to ltb-4
AU3959193A (en) Heterocyclic compounds and their use in the treatment of type II-diabetes
FI970534A (sv) Förfaranden och kompositioner som är användbara vid profylax och behandling av endotoxinrelaterade tillstånd
FI954964A (sv) Användande av vWF-haltiga koncentrat som kombinationsterapi vid terapi med antitrombotika och fibrinolytika
FI960850A (sv) Användning av kinoxaliner i kombination med proteasinhibitorer som läkemedel vid behandling av AIDS och/eller HIV-infektioner
NO970257L (no) Bestemmelse av tonisk ovarie-östrogen sekresjon i utvidede terapeutiske regimer
GB2294637B (en) Therapeutic compositions and methods of use
AU2548795A (en) Antithrombin agents in treatment of asthma
EP0750511A4 (en) TREATMENT OF INFLAMMATION BY ADMINISTRATION OF SPECIFIC SULFATASE ENZYMES AND / OR A SULFATATION INHIBITOR
IL123156A0 (en) Benzenesulphonamide derivatives their preparation and their application in therapy
DE69528261T2 (de) Benzopyrane und deren verwendung als therapeutische mittel
FI972637A0 (sv) Användning av K-gruppens vitamin vid behandling av hyperparatyreoidism
BR9709219A (pt) Utilização do brometo de pinaverium na prevenção dos fenômenos proliferativos das células do trata hepatodigestivo e das doenças que daí resultam
GB9401745D0 (en) Improvements in and relating to the administration of medicaments or therapeutic substances
ZA982355B (en) Derivatives of n-(arginyl) benzenesulphonamide their preparation and their use in therapy
IL109356A0 (en) N-substituted-2-azetidinones and their use in the preparation of n-unsubstituted-2-azetidinones